Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.


From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Reaxense aids in their synthesis and provision.


In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.


Our top-notch dedicated system is used to design specialised libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.


Our library stands out due to several important features:


  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.

  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.

  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.

  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
Q16877

UPID:
F264_HUMAN

ALTERNATIVE NAMES:
6PF-2-K/Fru-2,6-P2ase testis-type isozyme

ALTERNATIVE UPACC:
Q16877; Q5S3G5; Q5XLC2; Q64EX5

BACKGROUND:
6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 4, identified by the alternative name 6PF-2-K/Fru-2,6-P2ase testis-type isozyme, is integral to the metabolic pathway that synthesizes and breaks down fructose 2,6-bisphosphate. This enzyme's activity is key in balancing the flux between glycolysis and gluconeogenesis, thereby influencing energy homeostasis within the cell.

THERAPEUTIC SIGNIFICANCE:
Exploring the function of 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 4 offers a promising avenue for developing novel therapeutic approaches. Given its central role in managing cellular energy metabolism, targeting this enzyme could yield breakthroughs in treating metabolic diseases.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.